# Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

> **NCT02538705** · NA · COMPLETED · sponsor: **Artgen Biotech** · enrollment: 35 (actual)

## Conditions studied

- Ulcers Related to Diabetic Foot Syndrome

## Interventions

- **DRUG:** Neovasculgen

## Key facts

- **NCT ID:** NCT02538705
- **Lead sponsor:** Artgen Biotech
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-01-01
- **Final completion:** 2016-01-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538705, "Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02538705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*